Rush University Medical Center, Chicago, IL

Slides:



Advertisements
Similar presentations
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Advertisements

ACC 2015 Jae K. Oh, MD On Behalf of the US CoreValve Investigators Remodeling of Self-Expanding Transcatheter Aortic Valve Is Responsible for Regression.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC.
University Heart Center Hamburg
Dr Martyn Thomas Director of Cardiac Services Guys and St Thomas NHS Foundation Trust A Member of Kings Health Partners London.
Trans-catheter Aortic Valve Replacement: a UK update. Dr Martyn Thomas Guys and St Thomas’ Hospital.
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
Axel Linke University of Leipzig Heart Center, Leipzig, Germany Sabine Bleiziffer German Heart Center, Munich, Germany Johan Bosmans University Hospital.
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
Secondary Intervention in Unfavorable AAA Neck Anatomy Congress Symposium 2007 John T. Collins, MD Borgess Medical Center Kalamazoo, MI.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Martin B. Leon, MD on behalf of the PARTNER Investigators TCT 2010; Washington, DC; September 23, 2010 Transcatheter Aortic Valve Implantation in Inoperable.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Transcatheter Cardiovascular Therapeutics 2008 (October 12-17, 2008 · Washington, DC) First-in-Human Report: Initial Experience with a Stentless and Retrievable.
Martin B. Leon, M.D., Craig R. Smith, M.D., Michael Mack, M.D., D. Craig Miller, M.D., Jeffrey W. Moses, M.D., Lars G. Svensson, M.D., Ph.D., E. Murat.
Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,
TAVR in Patients With Chronic Kidney Disease
VSD post TAVR: Mechanisms, Presentation and Management
Outcomes in the CoreValve US High-Risk Pivotal Trial in Patients with a Society of Thoracic Surgeons Predicted Risk of Mortality Less than or Equal to.
PERCUTANEOUS PULMONARY VALVE REPLACEMENT:
Issues and Current Situations in the Development of Endovascular Treatment Devices for Pediatric Cardiology in the US – US Industry Dan Gutfinger, MD,
Extending the Boundaries of TAVR: Future Directions
Clinical Trial Design for Second Generation TAVI - Academic View
Trans- catheter aortic valve replacement vs
Overview of the 2012 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting on the Edwards SAPIEN.
Late breaking news in heart valve disease
TAVR Medtronic CoreValve® Subclavian Approach Clinical Data
The Lotus Device Design & FIM Experiences with a Repositionable Self Expanding Percutaneous Aortic Valve Ian T. Meredith MBBS, BSc(Hons), Ph.D, FRACP,
Anita W. Asgar MD, FRCPC, FACC Montreal Heart Institute
Transcatheter Aortic Valve Replacement Using the Lotus Valve with Depth Guard First Report from the RESPOND Extension Study Nicolas M Van Mieghem, MD,
Design & Product Development Larry L Wood
Direct Flow Medical Experience with a Conformable, Repositionable, Retrievable, Percutaneous Aortic Valve Reginald Low MD University of California,Davis.
Updates From NOTION: The First All-Comer TAVR Trial
Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.
Review of the Latest OUS Data from the Self-Expanding Valve Studies
Percutaneous Heart Valves: Standards and Modeling Timothy Kelley, MS
Heart Valve Thrombosis & Neuro-Outcomes
MedStar Washington Hospital Center Cardiac Catheterization Conference
30-Day Safety and Echocardiographic Outcomes Following Transcatheter Aortic Valve Replacement with the Self-Expanding Repositionable Evolut PRO System.
Trans-Apical Aortic Valve Implant:
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
Early Outcomes with the Evolut R Repositionable Self-Expanding Transcatheter Aortic Valve in the United States Mathew Williams, MD, For the Evolut R US.
University of Pennsylvania
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,
Direct Flow Medical Experience with a Conformable, Repositionable Retrievable Percutaneous Aortic Valve Reginald Low MD University of California, Davis.
Early Feasibility Studies Investigator Perspective
Keith Dawkins MD FRCP FACC FSCAI Global Chief Medical Officer
Panel Discussion: What Should Be the Optimal Design for Percutaneous Aortic Valve Therapy? Raoul Bonan, MD Institut de Cardiologie de Montreal.
Opportunities to Study Valve Iterations and Modifications in the US
Niv Ad, MD Chief, Cardiac Surgery Professor of Surgery, VCU
CoreValve Continued Access Study Shows Continued Improvement in 1-Year Outcomes With Self-Expanding Transcatheter Aortic Valve Replacement Steven J. Yakubov,
Progress with the Sadra Medical Lotus™ Valve System
Axel Linke University of Leipzig Heart Center, Leipzig, Germany
Improved Technology: Evaluating Device Modifications
One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.
Second Generation Valves: What Will Be Different?
University Heart Center Hamburg
Balloon-Expandable Transcatheter Valve System : OUS Data
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS,
Is Open Heart Surgery Too Risky For You? Opt for a Minimally Invasive Procedure.
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Nat. Rev. Cardiol. doi: /nrcardio
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
Median total new lesion volume
PARTNER 2A Trial design: Intermediate-risk patients with aortic stenosis (STS PROM score 4-8%) were randomized to undergo either TAVR or SAVR, stratified.
Michael J. Davidson, MD, Frederick G. P. Welt, MD, Andrew C
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Presentation transcript:

Rush University Medical Center, Chicago, IL First Prepackaged 26 mm Transcatheter Aortic Valve Premounted in a 14 Fr Delivery system: Miniswine implant in the Pulmonary Position of the Colibri Heart Valve Ziyad M. Hijazi MD MPH, R. David Fish MD, David Paniagua MD, Carlos Mejia BA, Eduardo Induni MD, David E. Paniagua BS, Elizabeth Gonzalez BA and Damien Kenny, MB MRCPCH Rush University Medical Center, Chicago, IL St. Luke’s Episcopal Hospital / Texas Heart Institute, Houston, TX, Hospital México, Universidad de Costa Rica, San José Costa Rica, Michael E. DeBakey VA Medical Center, ColibriHeart Valve LLC, Houston, TX

I have no relevant disclosures to report Damien Kenny, MB, MRCPCH I have no relevant disclosures to report

Background: Current THV Transcatheter heart valves (THV) are in rapid development, but currently have important deficiencies that complicate implantation and increase both technical and clinical risk. Implanted bioprosthetic heart valves are stored, transported, and delivered for use in a jar of solution. Before implantation, they must be rinsed and are prepared for use in a "wet" state that imposes higher packing volume and delivery profile. THV must be mounted and crimped upon the delivery catheter by the operators in the cath lab, which can be a source of delay, error and inconsistency. Available THV require large diameter delivery catheters of 18 Fr or larger, which may complicate transfemoral delivery and cause vascular injury and bleeding.

PARTNER Cohort B: TAVI Complications TAVI resulted in more frequent complications at 30 days ENDPOINT TAVI % Standard % P Major vascular complications 16.2 1.1 0.0001 Major bleeding episodes 16.8 3.9 Major strokes 5.0 0.06

Cause of Complications & Mortality? Stroke => 66.7 % Mortality 22 and 24 Fr Sizes Cause of Complications & Mortality?

Colibri Heart Valve A new THV that addresses these shortcomings has been developed with core features: Low profile Folded, thin pericardium membrane Dry valve, pre-mounted at manufacture Fully integrated, pre-packaged delivery system Storage and transport in dry state Ready to use directly from package into the patient Aortic and Pulmonary valve models Though dry at insertion, the membrane leaflets function immediately on deployment in the body.

Colibri Heart Valve – Low Profile Dry, Integrated, Pre-Packaged, Ready-to-use, Low-profile Colibri Heart Valve – Low Profile Special porcine pericardium tissue processing permits a dry membrane configuration that reduces THV profile: 22 – 26 mm : 14 Fr 27 – 30 mm : 16 Fr Dry, Integrated, Pre-Packaged, Ready-to-use, Low-profile

Thin-membrane, high tensile strength valve (>30 Mpa) : 3 x industry standard Very low mass and packing volume ➠ Low profile Aortic or pulmonary valve models: Balloon-expandable frame THV Premounted in delivery system in a DRY state DRY valve does not require rinsing, rehydration, or mounting in cath lab ➠ inserted directly from package into the body

Key to Low Profile and Dry Membrane: High Tensile Strength Ultimate Tensile Strength Tissue Strength Superior to Industry Standard Key to Low Profile and Dry Membrane: High Tensile Strength 50 MPa Minimum 30 MPa 12 MPa Aortic valve native operating load =13 KPa Wet Tissue Stress-Strain Samples

Operation in Pulse Duplicator

6 month sterility & accelerated aging confirmed Very low mass and packing volume ➠ Successful implants of DRY, 1 - month AGED, PRE-PACKAGED valves in dogs: Confirmed immediate hemodynamic competence in orthotopic implants in dogs: 5 Pulmonary + 3 Aortic Confirmed 1 - month chronic performance: 4 Pulmonary First – in – Man clinical pilot study scheduled for 2011 ICE: Dry PulmV 1 mo

ICE: Chronic Pulm - THV Long Axis from RVOT THV stored DRY for 1 month Dog Pulm Valve Implant 1 Month Chronic Explant

Mini-swine THV Implant in Pulmonary Position Dr. ZiyadHijazi Rush University Medical Center Mini-swine THV Implant in Pulmonary Position 22-26 mm TAVI valve 14 Fr Introducer

Mini-swine THV Implant in Pulmonary Position Dr. ZiyadHijazi Rush University Medical Center

22-26 mm TAVI valve Pulmonary Implant at 24 mm 14 Fr Introducer

Conclusions - 1 The folded, thin-membrane design of the Colibri valve achieves a very low-profile valve without a sacrifice in tensile strength, static loading or leakage. In vitro testing shows that low leaflet mass achieves low opening gradients and high coaptation efficiency at maximum acceleration. The Colibri dry-membrane valve functions immediately on deployment in both aortic and pulmonary positions in dog and sheep models. Chronic function of pre-mounted, pre-packaged dry THV implants is confirmed at 1 month in the dog model in the pulmonary position.

Conclusions - 2 Transcatheter implantation of the Colibri dry-membrane THV that is pre-mounted and pre-packaged in an integrated 14 Fr (22-26 mm THV) delivery system is feasible. A mini-swine pulmonary implant series is initiated in preparation for a first-in-human trial. The Colibri valve and integrated delivery system may increase the success and efficiency of THV procedures by easing femoral access and reducing procedural time, complexityand complications.

Thank You